Labetalol S.A.L.F. (Labetalol Hydrochloride)

Labetalol blocks alpha‑1 adrenergic receptors, causing blood‑vessel dilation, and non‑selective beta‑adrenergic receptors, decreasing heart rate and contractility. This dual action reduces both peripheral vascular resistance and cardiac output, leading to a controlled fall in systemic blood pressure.

The dosing regimen for Labetalol S.A.L.F. is individualized and determined by the prescribing clinician. Typically, an initial intravenous bolus is followed by a titrated infusion, with the exact amount adjusted based on the patient’s blood‑pressure response and clinical condition.

Safety data for labetalol during pregnancy and lactation are limited. It may be used when the potential benefit justifies the risk, especially in severe hypertension, but clinicians should evaluate each case carefully and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Labetalol’s combined alpha‑ and beta‑blocking profile distinguishes it from pure vasodilators like nitroprusside or selective beta‑blockers. It offers rapid blood‑pressure control with less reflex tachycardia than pure vasodilators, making it useful when both heart rate and vascular tone need simultaneous management.

Labetalol S.A.L.F. should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

The product is given by intravenous injection or infusion. An initial bolus may be administered, followed by a continuous infusion that is titrated to achieve the desired blood‑pressure target, with frequent monitoring of hemodynamic parameters.

Serious adverse events include severe hypotension, bronchospasm especially in patients with asthma, hepatic dysfunction, and allergic reactions such as anaphylaxis. Prompt recognition and management of these reactions are essential during therapy.

Contraindications include known hypersensitivity to labetalol, severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and uncontrolled asthma or bronchospastic disease. Caution is also advised in patients with significant hepatic impairment.